Clinical Trial Update: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating a COVID-19 booster vaccine in autoimmune-disease non-responders was terminated, with results posted on 2025-08-22.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Dermatomyositis
• Juvenile Idiopathic Arthritis
• Multiple Sclerosis
• Pemphigus Vulgaris
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Status: TERMINATED | Results posted: 2025-08-22